SERB Pharmaceuticals

Who owns SERB Pharmaceuticals?
SERB Pharmaceuticals is a privately held company. Jeremie Urbain serves as chairman. The company does not publicly disclose its shareholder structure, and it is not owned by a larger pharmaceutical corporation.

Is SERB Pharmaceuticals publicly traded?
No. SERB is a private company. Its shares do not trade on any stock exchange.

When was SERB founded?
The original SERB (Société d'Études et de Recherches Biologiques) was founded in Paris in 1951. The modern company took shape through the 2021 acquisition of BTG Specialty Pharmaceuticals and a 2022 rebrand unifying SERB, BTG Specialty Pharmaceuticals, and Veriton Pharma.

Who makes Voraxaze?
Voraxaze (glucarpidase) is made by SERB Pharmaceuticals. SERB acquired the product in March 2021 as part of its approximately $800 million purchase of BTG Specialty Pharmaceuticals from Boston Scientific. BTG had originally launched Voraxaze in 2012.

What does SERB Pharmaceuticals make?
More than 70 medicines across two franchises: emergency medicine and antidotes (CroFab, DigiFab, Voraxaze, Radiogardase, and CBRN countermeasures) and rare disease treatments in oncology, neurology, and metabolic disorders, including Danyelza.

Where is SERB based?
The company is headquartered in Paris, France. Its US operations run through BTG Pharmaceuticals in West Conshohocken, Pennsylvania, and it has manufacturing and R&D sites in Wales, Australia, Utah, and France.

The original SERB, Société d'Études et de Recherches Biologiques, was founded in Paris in 1951. For five decades it remained a small French pharmaceutical business focused on niche hospital products, employing just 10 people as recently as 2001.

The transformation began in the 2010s under chairman Jeremie Urbain, as the company pursued a rollup of neglected and specialty products that larger pharmaceutical companies no longer prioritized. The acquisition strategy centered on drugs with small patient populations but essential clinical roles: antidotes, rescue medicines, and treatments for rare conditions that face chronic supply problems in conventional pharma portfolios.

The defining transaction came in March 2021, when SERB completed the approximately $800 million cash acquisition of BTG Specialty Pharmaceuticals from Boston Scientific. BTG plc, the British company that had assembled the antidote and specialty portfolio including CroFab (rattlesnake antivenom), DigiFab (digoxin antidote), and Voraxaze (glucarpidase for methotrexate toxicity), had itself been acquired by Boston Scientific in 2019. Boston Scientific retained BTG's interventional medicine business and divested the specialty pharmaceuticals division to SERB, which reorganized it as a self-sufficient business with US commercial operations and biomanufacturing sites in Wales, Australia, and Utah.

A further acquisition brought Veriton Pharma into the group, and in December 2022 the three legacy entities relaunched under a unified identity as SERB Pharmaceuticals. The combined business employed more than 400 people at the time and supplied medicines to more than 80 countries.

Growth continued through the mid-2020s. In 2024, the company acquired a frostbite treatment from CiVi Biopharma and named Vanessa Wolfeler, previously a Sanofi executive who led the US Dupixent and rare disease businesses, as CEO. In 2025, SERB announced the $412 million all-cash acquisition of Y-mAbs Therapeutics, adding the neuroblastoma drug Danyelza and expanding its rare oncology presence. The workforce grew past 600 employees across offices in the US, Europe, the Middle East, and Australia.